Therefore, it is necessary to explore the ERCC1expression pattern to determine the effect of ERCC1 expression on the clinicopathological features and prognosis of patients with HER2-positive breast cancer treated with trastuzumab. Here, ERBB2 is linked to breast carcinoma.